Impact of Intraoperative ICG on Functional Outc in RARP

Recruiting now · Early Phase 1

Conditions studied: Prostate Adenocarcinoma

In brief

This is a pilot, 3 phases open-label feasibility study with the 3rd phase consisting of randomized 2-arm intervention trial, to assess the systematic use of indocyanine green (ICG) in subjects with prostate adenocarcinoma during robot-assisted radical prostatectomy and its impact on sexual function outcomes at 12 months postoperatively.

Key facts

Study ID

NCT06446648

Run by

University of California, Irvine

People needed

400

Starts

2024-07-12

Expected to finish

2030-07-01

Last updated by the study team

2026-03-03

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• 1. Subjects must be ≥18 years old and male.
• 2. Histologically/pathologically confirmed localized prostate adenocarcinoma.
• 3. Most recent preoperative Sexual Health Inventory for Men (SHIM) score ≥10.
• 4. Subjects who are candidates for good nerve sparing preoperatively determined by the investigator by assessing imaging findings.
• 5. Ability to read, write and understand and willingness to sign a written informed consent.
• 6. Subjects must pass medical clearance from primary care provider and cardiologist, if applicable.
• 7. Subject must be determined to be medical fit for RARP by the investigator.

You may not qualify if…

• 1. No locally advanced or metastatic prostate adenocarcinoma.
• 2. Preoperative diagnosis of erectile dysfunction with any use of invasive interventions such as intrapenile injections and intrapenile prosthesis implants. Oral interventions are acceptable and are not exclusionary.
• 3. Received neoadjuvant treatment for high-risk prostate cancer or received prior focal treatment of the prostate or prior definitive radiotherapy.
• 4. History of allergic reactions or hypersensitivity attributed to iodide compounds, ICG, or any component of ICG.
• 5. Subjects who are preoperatively not foreseen as ideal candidates for nerve sparing interventions by the investigator.
• 6. Subjects who are unable to comply with study and follow-up procedures as judged by the investigator.
• 7. Subjects who are illiterate.
• 8. Other serious, uncontrolled concomitant diseases that may affect protocol compliance or interpretation of outcomes, including active opportunistic infections or advanced (severe) infections, or uncontrolled diabetes.
• 9. Any other disease, metabolic disorder, or abnormal finding upon physical examination or laboratory examination that makes the subject unsuitable for receiving the intervention, affects the interpretation of study outcomes, or poses risks to subject safety, as determined by the investigator.

Where it is running

• Chao Family Comprehensive Cancer Center University of California, Irvine — Orange, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.